Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1982 12
1983 3
1984 2
1985 4
1986 9
1987 13
1988 7
1989 18
1990 23
1991 18
1992 15
1993 11
1994 18
1995 10
1996 16
1997 18
1998 14
1999 10
2000 10
2001 14
2002 7
2003 17
2004 4
2005 8
2006 9
2007 9
2008 6
2009 11
2010 8
2011 5
2012 14
2013 8
2014 8
2015 7
2016 5
2017 6
2018 3
2019 2
2020 6
2021 2
2022 3
2023 3
2024 3
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

384 results

Results by year

Filters applied: . Clear all
Page 1
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G; STAR*D Investigators Group. Rush AJ, et al. Control Clin Trials. 2004 Feb;25(1):119-42. doi: 10.1016/s0197-2456(03)00112-0. Control Clin Trials. 2004. PMID: 15061154 Clinical Trial.
After receiving citalopram (level 1), participants without sufficient symptomatic benefit are eligible for randomization to level 2 treatments, which entail four switch options (sertraline, bupropion, venlafaxine, cognitive therapy) and three citalopram augment options (bupropion …
After receiving citalopram (level 1), participants without sufficient symptomatic benefit are eligible for randomization to level 2 treatmen …
Buspirone for early satiety and symptoms of gastroparesis: A multi-centre, randomised, placebo-controlled, double-masked trial (BESST).
Parkman HP, Yates KP, Sarosiek I, Bulat RS, Abell TL, Koch KL, Kuo B, Grover M, Farrugia G, Silver P, Abdullah A, Maurer AH, Malik Z, Miriel LA, Tonascia J, Hamilton F, Pasricha PJ, McCallum RW; NIDDK Gastroparesis Clinical Research Consortium. Parkman HP, et al. Aliment Pharmacol Ther. 2023 Jun;57(11):1272-1289. doi: 10.1111/apt.17479. Epub 2023 Apr 13. Aliment Pharmacol Ther. 2023. PMID: 37052334 Free PMC article. Clinical Trial.
BACKGROUND: Patients with gastroparesis and related disorders have symptoms including early satiety, postprandial fullness and bloating. Buspirone, a 5-HT(1) receptor agonist, may improve fundic accommodation. AIM: To determine if buspirone treatment improves early …
BACKGROUND: Patients with gastroparesis and related disorders have symptoms including early satiety, postprandial fullness and bloating. …
Buspirone: anxiolytic?
Pecknold JC, Familamiri P, Chang H, Wilson R, Alarcia J, McClure DJ. Pecknold JC, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(5-6):639-42. doi: 10.1016/0278-5846(85)90032-6. Prog Neuropsychopharmacol Biol Psychiatry. 1985. PMID: 2868495 Clinical Trial.
Dizziness was the most prominent adverse effect in the buspirone group, whereas the diazepam group had more adverse effects including sedation, fatigue, dizziness and impaired concentration. Withdrawal symptoms were more evident in the diazepam group than the buspirone …
Dizziness was the most prominent adverse effect in the buspirone group, whereas the diazepam group had more adverse effects including …
Consistent differential effects of bupropion and mirtazapine in major depression.
Strobl EV. Strobl EV. J Affect Disord. 2025 Nov 1;388:119551. doi: 10.1016/j.jad.2025.119551. Epub 2025 May 29. J Affect Disord. 2025. PMID: 40449742 Free article. Clinical Trial.
In STAR*D, bupropion monotherapy produced greater improvement in hypersomnia than venlafaxine in Levels 2 and 2 A (n=686, difference = 0.384, p(FWER)=0.007). Bupropion augmentation outperformed buspirone augmentation for increased weight, increased appetite, and fatigue in …
In STAR*D, bupropion monotherapy produced greater improvement in hypersomnia than venlafaxine in Levels 2 and 2 A (n=686, difference = 0.384 …
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.
Schneider RB, Auinger P, Tarolli CG, Iourinets J, Gil-Díaz MC, Richard IH. Schneider RB, et al. Parkinsonism Relat Disord. 2020 Dec;81:69-74. doi: 10.1016/j.parkreldis.2020.10.020. Epub 2020 Oct 13. Parkinsonism Relat Disord. 2020. PMID: 33070009 Free PMC article. Clinical Trial.
In the buspirone group, 7 (41%) failed to complete the study on drug, 5 due to intolerability. The median buspirone dosage was 7.5 mg twice daily. No serious adverse events occurred. A total of 9 (53%) buspirone participants experienced adverse events consist …
In the buspirone group, 7 (41%) failed to complete the study on drug, 5 due to intolerability. The median buspirone dosage was …
Comparison of the Efficacy of Buspirone and Placebo in Childhood Functional Abdominal Pain: A Randomized Clinical Trial.
Badihian N, Yaghini O, Badihian S, Shahsanai A, Saneian H. Badihian N, et al. Am J Gastroenterol. 2020 May;115(5):756-765. doi: 10.14309/ajg.0000000000000589. Am J Gastroenterol. 2020. PMID: 32221160 Clinical Trial.
RESULTS: Ninety-five patients completed the 4-week therapy (48 and 47 in buspirone and placebo groups, respectively). Both buspirone and placebo reduced pain after 4 weeks of treatment, and these effects were persistent 8 weeks after medication discontinuation (P &l …
RESULTS: Ninety-five patients completed the 4-week therapy (48 and 47 in buspirone and placebo groups, respectively). Both buspiro …
A Prospective Open-Label Trial of Buspirone for the Treatment of Anxiety in Williams Syndrome.
Thom RP, Renzi D, Pecukonis M, Mullett J, Ravichandran C, McDougle CJ. Thom RP, et al. J Child Adolesc Psychopharmacol. 2025 May;35(4):222-230. doi: 10.1089/cap.2024.0124. Epub 2024 Dec 17. J Child Adolesc Psychopharmacol. 2025. PMID: 39686774 Clinical Trial.
Results: Buspirone use (mean dose, 22.6 mg per day) was associated with a reduction in anxiety severity, with Cohen's d estimate of -4.02 for the PARS. ...Given these findings, a double-blind, placebo-controlled study of buspirone in WS is warranted....
Results: Buspirone use (mean dose, 22.6 mg per day) was associated with a reduction in anxiety severity, with Cohen's d estimate of - …
A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.
Bergeria CL, Tan H, Antoine D, Weerts EM, Huhn AS, Hobelmann JG, Dunn KE. Bergeria CL, et al. Exp Clin Psychopharmacol. 2023 Feb;31(1):194-203. doi: 10.1037/pha0000550. Epub 2022 Mar 10. Exp Clin Psychopharmacol. 2023. PMID: 35266779 Free PMC article. Clinical Trial.
Greater decreases in withdrawal were observed during Week 2 of stable buspirone relative to Week 1 of stable buspirone. Participants also reported significant increases in sleep duration and significant decreases in latency to sleep onset. This study provides furthe …
Greater decreases in withdrawal were observed during Week 2 of stable buspirone relative to Week 1 of stable buspirone. Partic …
Buspirone in levodopa-induced dyskinesias.
Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Bonifati V, et al. Clin Neuropharmacol. 1994 Feb;17(1):73-82. doi: 10.1097/00002826-199402000-00008. Clin Neuropharmacol. 1994. PMID: 8149361 Clinical Trial.
The duration of the study was 3 weeks, for both buspirone and for placebo treatment. Chronic therapies remained unchanged. The extrapyramidal symptoms, dyskinesias, and anxious/depressive symptoms were evaluated at the beginning of the study and after the buspirone …
The duration of the study was 3 weeks, for both buspirone and for placebo treatment. Chronic therapies remained unchanged. The extrap …
Assessing the efficacy and safety of combined buspirone and venlafaxine treatment in late-life depression accompanied by cognitive impairment: A randomized controlled trial.
Hu S, Chen K, Xu Q, Wang F, Na W. Hu S, et al. Gen Hosp Psychiatry. 2024 Nov-Dec;91:1-10. doi: 10.1016/j.genhosppsych.2024.09.001. Epub 2024 Sep 3. Gen Hosp Psychiatry. 2024. PMID: 39243483 Clinical Trial.
While antidepressants like venlafaxine and anxiolytics such as buspirone are effective for treating depression, their effects on cognitive function remain less well-understood. ...OBJECTIVE: This study aimed to evaluate the clinical efficacy and safety of combined buspi …
While antidepressants like venlafaxine and anxiolytics such as buspirone are effective for treating depression, their effects on cogn …
384 results